Search

Displaying results 2241 - 2250 of 10000 in total
  1. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%
  2. Drug

    Quaternium-18

    go.drugbank.com/drugs/DB11305
    ApprovedWithdrawn

    Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.

  3. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.

  4. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors … Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency.

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  5. Drug

    Doxofylline

    go.drugbank.com/drugs/DB09273
    Investigational

    As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. … Unlike theophylline, doxofylline does not affect calcium influx and does not antagonize the actions of calcium channel blockers which could explain reduced cardiac adverse reactions associated with the

  6. Drug

    Cinpanemab

    go.drugbank.com/drugs/DB16127
    Investigational

    Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).

    Synonyms: Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal
  7. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

  8. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. … Studies demonstrated that reslizumab was not effective in various asthma outcomes in patients without eosinophilia [A31577]. Reslizumab was developed by Teva Pharmaceuticals.

  9. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  10. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    If Chagas disease is left untreated, life-threatening sequelae may result.[L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. … Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas.